China’s Rare Earth Export Clampdown: A Ticking Time Bomb for U.S. Medical Devices and Patient Lives
Executive Summary In an escalating trade war, China’s tightened export controls on rare earth elements (REEs)—announced in April 2025 and expanded in October 2025—pose an immediate and severe threat to the U.S. healthcare sector. These restrictions, which include licensing requirements and outright bans on exports to entities linked to foreign militaries, target seven medium and heavy REEs (samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium) initially, with five more added recently. As the U.S. imports over 80% of its REEs from China, disruptions could halt production of critical medical technologies, leading to delays in diagnostics, treatments, and surgeries. This analysis examines the most vulnerable medtech products, their reliance on REEs, and the cascading risks to patient safety, drawing on data from industry reports, government assessments, and scientific studies. With stockpiles lasting mere months and domestic production ramping up too slowly,…
